Andere Sprachen Jenscare Scientific Co., Ltd.

Aktien

A3DXAZ

CNE100005KC9

9877

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:42 28.06.2024			% 5 Tage	% 1. Jan.
3,99 ^HKD	+0,76 %		-0,50 %	-82,03 %

25.04.	Antrag für LuX-Valve von Jenscare Scientific von der NMPA nicht genehmigt, Aktienkurs fällt um 11%	MT
27.03.	Jenscare Scientific Co. Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Jenscare Scientific's LuX-Valve Application Not Approved by NMPA, Share Prices Drop 11%	25.04.
Jenscare Scientific Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Jenscare Scientific's Mitral Valve Device Completes Enrollment for Confirmatory Clinical Trials	25.03.
Jenscare Scientific Co., Ltd. Announces Completion of the Enrollment of JensClip for Confirmatory Clinical Trial and One-Month Follow-Up	25.03.
Jenscare Scientific Secures HKEX Nod for H Share Circulation	19.03.
Jenscare Scientific Co., Ltd. Completes the First Clinical Implantation in Brazil	28.02.
Jenscare Scientific’s CEO, CFO Boost Stake in Firm	26.01.
Jenscare Scientific Unit Concludes 1st Clinical Implantation of PFO Occluder System	03.01.
Jenscare Scientific Co., Ltd. Completes the First Clinical Implantation of Omniseal	03.01.
Jenscare Scientific to Buy Back Shares	29.12.
Jenscare Scientific Shareholders Approve of Sale of 22.48% Interest in Congenital Heart Disease Device Maker	22.12.
Jenscare Scientific to Divest 22.5% Stake in Medical Device Maker	29.11.
Jenscare Releases Results of Confirmatory Trial for Tricuspid Valve Replacement in London Meet	28.11.
Jenscare Scientific Co., Ltd. Announces One-Year Results of the Confirmatory Clinical Trial of the LuX-Valve Transcatheter Tricuspid Valve Replacement System	28.11.
Jenscare Scientific Enrolls First Patient for Atrial Appendage Occluder System Trial	13.11.
Jenscare Presents Results of Tricuspid Valve Replacement System at US Conference	31.10.23
Jenscare Scientific Co., Ltd. Announces Lux-Valve Plus Travel II Results Released At the 2023 TCT in the U.S	31.10.23
Jenscare Shares Surge 16% After China Grants Priority Approval for Aortic Heart Valve System	30.10.23
Jenscare Scientific Co., Ltd. Announces Registration Application of Ken-Valve, the Transcatheter Prosthetic Aortic Heart Valve System Successfully Enters the Priority Approval Process	30.10.23
Jenscare Scientific Applies Valve Replacement System Under Fee-for-Service Scheme in Asia-Pacific; Shares Tumble 9%	20.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Jenscare Scientific Co., Ltd.

Aktien

A3DXAZ

CNE100005KC9

9877

Andere Sprachen

Filter